Other
Recurrent
0
Pipeline Programs↗
14
Active Trials↗
6
Companies Involved↗
Recurrent is an early-stage landscape with 0 programs across 6 companies. The most active players are Novartis, Vector Oncology, Gynecologic Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
69
clinical trials
Completed28 · 41%
Terminated15 · 22%
Recruiting7 · 10%
Withdrawn6 · 9%
Unknown status6 · 9%
Active, not recruiting6 · 9%
Other1 · 1%
Clinical Trials
Trial Activity
69 trials
Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease
Active, not recruiting·—·Phase 4·NCT03406338·60 enrolled
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03961971·16 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)